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ABSTRACT 
The primary objective of the present study was to prepare repaglinide microspheres for the sustained delivery of the drug for better 
patient care in the management of diabetics. The biodegradable microspheres of repaglinide is prepare using poly (lactic-co-glycolic 
acid) (PLGA) by emulsion solvent evaporation technique. The microspheres are prepared with different drug-to-carrier ratios and 
considering other variables (i.e. solvent, surfactant and stirrer speed) as well. The evaluation of microspheres prepared are perform 
on the basis of various parameters  like particle size, percentage yield, drug entrapment efficiency, surface morphology, drug-
polymer interaction (FT-IR study), in vitro drug release kinetics and stability studies. SEM reveals that microspheres are spherical 
and has nearly smooth surface morphology. The percentage yield and drug entrapment efficiency is quite well for all the 
formulations. FT-IR spectra show that there is no chemical interaction between the drug and the polymer. The in vitro release study 
data shows that the repaglinide release from all the formulations are slow and sustained upto 7days. The various kinetic equations 
indicate that the in vitro drug release is of zero order release with initial burst from repaglinide microspheres. There is no appreciable 
difference is observed in the stability study observations. 
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INTRODUCTION: 
The recent era is of biodegradable polymers era and in 
the recent time more importance was given to modified 
release dosage forms to achieve and maintain therapeutic 
amount of drug in the blood or tissue to improve 
pharmacokinetics of drug and increase patient 
compliance as well as reducing side effects for a prolong 
period of time. 
 
Microspheres comprise matrix systems 
which contain drug throughout their structure and are 
potential candidates for oral controlled release. 
Microspheres can be defined as solid spherical particles 
ranging from 1 to 1000 μm in size 1. These particles 
consist of the drug which is the core material and a 
polymeric coating material. The coating material can be 
of various types ranging from natural polymers 
(chitosan, albumin, gelatin,) to synthetic polymers 
(PVA, PLGA, PEG, poly (ε-caprolactone), blok 
copolymers etc) 
2
. Among the various coating materials 
used for the development of sustained release 
formulations, PLGA has been reported to be 
advantageous as it is biodegradable, biocompatible, and 
has a very low glass temperature.  Apart from single 
PLGA now-a-days polymeric blend or diblock 
copolymer with protein repellents (like Poloxamer, 
Ploxamine and PEG) have been used to impart a stealth 
characteristic to polymeric micro/nano-particles and 
ultimately achieved controlled release of the drug.  This 
has led to its application in the preparation of different 
delivery systems in the form of microspheres, 
nanoparticles, and implants. Repaglinide belongs the 
meglitinide class of drugs is a fast- and short-acting drug 
with a very short plasma half-life (about 1 hr) and low 
bioavailability (50%) 
3
. Repaglinide
 
was chosen as the 
model drug in the present study for formulation of 
microspheres to achieve the controlled drug release 
profile suitable for peroral administration.   
MATERIALS AND METHODS: 
Materials 
Repaglinide and polymer were received as a gift sample 
from M/S Torrent Pharmaceuticals, Ahmedabad, India. 
Dichloromethane, Methanol, PVP, Polysorbate 80 was 
purchased from Loba Chem. Pvt. Ltd. And SD fine 
chemicals, Mumbai, India. All other reagents used were 
of analytical grade. 
Preparation of Microspheres 
Solvent evaporation method was used for the preparation 
of repaglinide microspheres.
 
Total 36 formulations were 
prepared by using different drug-to-carrier ratios 
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(1:2,1:1& 2:1), different stirrer speed (500rpm, 1000rpm 
& 1500 rpm), different surfactant (PVP & Polysorbate 
80) and different solvent (Methanol & DCM) An 
accurately weighed quantity (calculated) of the polymer 
was dissolved in 10 mL of dichloromethane/methanol 
and weight amount of repaglinide was dissolved in this 
polymer phase. This solution was emulsified in 100 mL 
of 0.5% PVP/Polysorbate 80 using continuous stirring 
for two hours at 500/1000/1500 rpm. The microspheres 
formed were filtered and washed three times with 50 mL 
of distilled water to remove surface adhered surfactants 
and dried at room temperature for 6 h. The dried 
microspheres were weighed and the % yield of the 
microspheres prepared was calculated using the formula 
4
. 
Percent Yield = Amount of Microspheres Obtained (g)/ 
Theoretical Amount (g) × 100 
Determination of the mean particle size and surface 
morphology: Particle size analysis was carried out by 
using optical microscopy.
 
About 100 microspheres were 
selected from each formulation randomly and their size 
was determined using an optical microscope fitted with a 
standard micrometer scale. Surface morphology and 
topography of the microspheres were examined by 
scanning electron microscopy (S-3000N, 
magnification=x5.0k, WD=33.3mm) and SEM 
photomicrographs of suitable magnification obtained. 
Determination of percentage drug entrapment: For 
determination of drug content a weighed quantity of the 
microspheres was crushed and suspended in phosphate 
buffer, pH 7.4 to extract the drug from the microspheres. 
After 24 h, the filtrate was assayed by HPLC with 
mobile phase of methanol: ammonium acetate buffer 
(pH-4) (80:20) at 242 nm for drug content. 
Corresponding drug concentrations in the sample were 
calculated from the calibration plot and the drug 
entrapment efficiency was calculated using the formula:  
% Entrapment Efficiency = Quantity of drug in 
Microspheres/Theoretical drug loading × 100 
FT-IR Study FT-IR spectra of repaglinide and 
microspheres were recorded in an FT-IR 
spectrophotometer to check the drug-polymer interaction 
and chemical integrity of the drug in the microspheres. 
Stability studies For the purpose of stability studies all 
the formulations were packed in 0.044 mm laminated 
aluminum foil and subjected to storage at elevated 
temperature and humidity conditions of 40°±2°C/75±5% 
RH in an environment chamber. Samples were 
withdrawn at the end of 1, 3 and 6 months and evaluated 
for physical properties, encapsulation efficiency, drug 
content, particle size and in-vitro drug release. 
In vitro Drug release studies Drug release studies were 
carried out using a USP type II dissolution apparatus and 
the dissolution vessel was filled with 900 mL of 0.1 N 
HCl and the temperature was kept constant at 37±0.5°C. 
Samples were withdrawn at predetermined time intervals 
with the same volume of fresh medium being added after 
each withdrawal. The sample was suitably diluted and 
assayed by HPLC method using PDA detector at 242 
nm. 
Kinetic modeling of drug release The dissolution 
profiles of selected formulations were fitted to zero 
order, first order, Higuchi’s and Kresmeyar-Peppas 
model to ascertain the kinetics of drug release. The 
regression coefficient (r
2
) was calculated for the curves 
obtained by regression analysis of the above plots. 
RESULTS AND DISCUSSION: 
Repaglinide microspheres with varying proportions of 
drug & polymer were prepared by the solvent 
evaporation method. The particle size was determined 
by optical microscopy and was found to increase with 
increasing polymer proportions. The % entrapment 
efficiency, % Drug content and mean particle size of the 
microspheres is shown in Table 1. Electron microscopy 
revealed that the microspheres were spherical with a 
nearly smooth surface [Figure 1]. The yield obtained for 
all batches was good and in the range of 83.54 ± 2.42 to 
88.28 ± 2.54%. The microspheres exhibited an increase 
in drug entrapment with an increase in the polymer ratio. 
As the stirrer speed goes high the particle size was lower 
and the PVP showed the better result as compare to 
polysorbate 80 in terms of release profile also. The FT-
IR spectra of repaglinide-loaded microspheres showed 
characteristic absorption peaks that were identical with 
the drug’s reference spectrum. This clearly indicated the 
stability of the drug during the microencapsulation 
process and revealed the absence of any drug-polymer 
interaction [Figures 2].The stability studies did not 
reveal any remarkable change in the drug content. This 
indicated that the formulation was stable in medium 
storage conditions. 
The release of repaglinide mainly depended upon the 
polymer concentration. The release rate of the drug from 
the microspheres was found to decrease drastically on 
increasing the polymer concentration.  Repaglinide 
release from all the formulations was found to be slow 
and sustained over 7 days. By the end of 7
th
 day, the 
formulations RMS6 and RMS24 were found to release 
49.6±1.06 and 43.7±1.31 of the loaded drug 
respectively. 
Release pattern from all the formulations showed an 
initial burst release followed a sustained drug release. 
The cumulative percentage drug release has been 
observed at the end of day 7. Various kinetic models 
applied, revealed that drug release was initially zero 
order followed by first order in both the formulations. 
The mechanism of drug release from RPG microspheres 
was studied by using Higuchi and Krsemeyer-peppas 
models. The r
2 
value shows that drug release was 
initially zero order (diffusion controlled release system) 
followed by first order (Diffusion and erosion controlled 
release). The in vitro release kinetics profiles of selected 
formulations have been shown in table 2 and Figure 3, 4, 
5 and 6. 
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Table 1: Characterization of Repaglinide loaded PLGA Microspheres 
Fln Code Formula EE (%) DC (%) PS (  
RMSA6 RPG:PLGA[1:2]+Dichloromethane+1500 Rpm + PVA 58.7±1.2 26.84±2.2 12.68±8.26 
RMSA24 RPG:PLGA[1:2]+Dichloromethane+1500 Rpm+ 
Polysorbate 80 
47.44±1.22 22.84±1.32 14.24±10.22 
 
Table 2: Release rate kinetics of Repaglinide loaded PLGA Microspheres 
Formulation 
Code 
Zero Order Release 
Rate 
First Order Release 
Rate 
Higuchi kinetics Krsemeyer- Pappas 
Kinetics 
Equation R
2
 Equation R
2
 Equation R
2
 Equation R
2
 
RMSA6 y = 6.0241x 
+ 2.25 
0.9064 y = -0.0377x 
+ 1.95 
0.9495 y = 18.505x 
+ 2.08 
0.9854 y = 0.3772x + 
1.37 
0.9983 
RMSA24 y = 6.0033x 
+ 5.15 
0.9797 y = -0.0347x 
+ 1.98 
0.9931 y = 17.802x - 
4.08 
0.9924 y = 0.668x + 
1.09 
0.9967 
 
                                                                
Figure 1: SEM Microphotograph of RMSA6 and RMSA24 Figure 2: FT-IR spectra obtained for pure 
Repaglinide and Repaglinide- loaded    microspheres                                              
                    
 
Figure 3: Zero Order drug release kinetics of RPG loaded 
Microsphere with PLGA     
 
Figure 4 : First order drug release kinetics of RPG loaded 
Microspheres with PLGA 
 
Figure 5 : Higuichi Model drug release kinetics of RPG 
loaded Micrspheres with PLGA 
 
Figure 6: Krsemeyer –Pappas Model drug release 
kinetics of RPG loaded Microsphees with PLGA 
CONCLUSION: 
Present results suggest that biodegradable microspheres 
of Repaglinide can be rationally employed as long acting 
formulation. The prepared microparticulate system 
ensures the sustained delivery of the drug for extended 
period of time. From the above data, it may be 
concluded that drug-loaded microspheres appear to be a 
suitable delivery system for repaglinide and may help in 
reducing the frequency of medication, improving patient 
compliance, cost of therapy and reducing side-effects. 
Engla et al                                                                                                              Journal of Drug Delivery & Therapeutics. 2017; 7(7):77-80                     
ISSN: 2250-1177                                                                                [80]                                                                             CODEN (USA): JDDTAO 
Acknowledgments: The author would like to thank M/S 
Torrent Pharmaceuticals, Ahmedabad, India for 
providing gift sample of drug and polymer. 
 
REFERENCES: 
1. Chowdary KPR, Koteswara N, Malathi K, Ethyl cellulose 
microspheres of glipizide: Characterization, in vitro and in 
vivo evaluation, IJP, 2004, 66, 412-6. 
2. Singh D, Saraf S, Dixit VK,  Saraf S, Formulation 
optimization of gentamicin loaded Eudragit RS100 
microspheres using factorial design study, BPB, 2008, 31, 
662-7. 
3. Jain SK, Agrawal GP, Jain NK, A novel calcium silicate based 
microspheres of repaglinide: in vivo investigations, JCR, 2006, 
113,111-6. 
4. Haznedar S, Dortunc B, Preparation and in vitro evaluation of 
Eudragit microspheres containing acetazolamide, IJP, 2004, 
269, 131-40. 
 
